- Hims & Hers has launched access to generic semaglutide in Canada through its digital health platform, offering personalized GLP-1 treatment plans for eligible patients starting at CAD $149/month.
- The launch follows Health Canada’s recent authorization of generic semaglutide, with the company highlighting the move as a step toward improving affordability and expanding access to obesity and metabolic health treatments across Canada.
- Through the platform, Canadian patients can connect with licensed local healthcare providers and receive personalized care plans that may include GLP-1 therapies, along with ongoing support focused on nutrition, movement, and sleep.
- Hims & Hers Canada noted that increasing availability of lower-cost generic semaglutide could help create a more competitive GLP-1 market in Canada, potentially improving access for patients facing cost barriers to treatment.
Takeaways
Hims & Hers is using generic semaglutide to anchor its Canadian weight‑loss and metabolic program, giving it a priced‑in, recurring revenue product at about CAD 149/month that undercuts branded Ozempic and fits cleanly into a subscription model.
For the Canadian GLP‑1 market, this move adds another national telehealth player alongside local platforms, increases competition for both in‑person clinics and other virtual providers, and should contribute to downward price pressure as more patients gain access to lower‑cost, domestically supplied generics prescribed by local clinicians.
Source: Businesswire
